VANCOUVER, British Columbia, July 6, 2026
Cannabix Technologies announced the successful detection of cocaine and its primary metabolite, benzoylecgonine, in human breath samples using its Marijuana Breath Test (MBT) platform. Breath samples were collected using the company’s Breath Collection Unit (BCU) and analyzed by Omega Laboratories utilizing liquid chromatography-mass spectrometry (LC-MS), a highly sensitive laboratory analytical technique. The achievement represents a significant milestone for Cannabix as it demonstrates that its breath-testing platform can identify trace levels of drug compounds beyond THC, expanding its potential use across workplace safety, transportation, industrial operations, rehabilitation programs, forensic toxicology, and law enforcement. The company believes the findings strengthen the clinical and commercial value of its breath-based drug detection technology by supporting future development of comprehensive multi-drug breath testing solutions.
Detection of Cocaine and Benzoylecgonine Supports Multi-Drug Testing Applications
The study successfully identified both cocaine and benzoylecgonine, the principal metabolite commonly used by forensic and clinical laboratories to confirm cocaine exposure. According to Cannabix, the results demonstrate that its integrated Marijuana Breath Test system—including the Breath Collection Unit, disposable Breath Cartridges, and Omega Laboratories’ laboratory-developed analytical method—can reliably capture and measure these extremely low-concentration compounds from exhaled breath. Detecting both the parent drug and its metabolite strengthens the scientific credibility of the testing platform while expanding its utility beyond cannabis detection. The company believes this capability creates new opportunities for organizations seeking more comprehensive and scientifically defensible drug testing solutions capable of evaluating multiple substances using a single breath collection process.
Breath Testing May Provide More Relevant Detection of Recent Drug Use
Unlike traditional biological testing methods that often detect historical drug exposure over extended periods, breath testing is designed to identify compounds associated with recent drug use, making it particularly valuable in safety-sensitive environments where impairment timing is an important consideration. Cannabix noted that detecting cocaine and benzoylecgonine in breath presents a significant technical challenge because these substances exist in extremely low concentrations following use. The successful application of LC-MS laboratory analysis demonstrates that the company’s testing platform can achieve the analytical sensitivity necessary for forensic-quality confirmation while maintaining a documented chain of custody. This capability may enhance decision-making in industries requiring accurate and timely assessment of recent drug exposure, including transportation, manufacturing, public safety, rehabilitation monitoring, and workplace compliance programs.
Advertisement
Cannabix Continues Expanding Breath Diagnostics Platform
The successful detection of cocaine and benzoylecgonine further expands Cannabix Technologies’ growing portfolio of breath-based diagnostic technologies. Initially developed for THC detection, the company’s Marijuana Breath Test platform is evolving into a broader multi-drug breath testing system capable of supporting a wider range of safety and forensic applications. By combining non-invasive breath collection with advanced laboratory confirmation through liquid chromatography-mass spectrometry, Cannabix aims to deliver scientifically validated testing solutions that complement existing toxicology methods while improving the ability to evaluate recent drug use. As demand continues to increase for practical, reliable, and legally defensible testing technologies, the company believes its expanding breath diagnostics platform positions it to address evolving needs across workplace safety, criminal justice, healthcare, and transportation sectors.
Source: Cannabix Technologies,press release
